{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:09:35Z","timestamp":1793286575453,"version":"4.5.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.semnephrol.2023.151477","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T08:26:23Z","timestamp":1706603183000},"page":"151477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies"],"prefix":"10.1016","volume":"43","author":[{"given":"Thita","family":"Chiasakul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Mullier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lecompte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0001","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrneph.2017.17","article-title":"Cardiovascular disease in haemodialysis: Role of the intravascular innate immune system","volume":"13","author":"Ekdahl","year":"2017","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151477_bib0002","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ekir.2020.03.010","article-title":"Hemodialysis does not induce detectable activation of the contact system of coagulation","volume":"5","author":"Francois","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0003","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/hdi.12586","article-title":"Platelet activation and clotting cascade activation by dialyzers designed for high volume online hemodiafiltration","volume":"22","author":"Tangvoraphonkchai","year":"2018","journal-title":"Hemodial Int"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0004","doi-asserted-by":"crossref","first-page":"13964","DOI":"10.1038\/s41598-018-31889-2","article-title":"Hemodialysis-related changes in phenotypical features of monocytes","volume":"8","author":"Liakopoulos","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0005","article-title":"Clotting of the extracorporeal circuit in hemodialysis\u2014beyond contact activated coagulation","author":"Engelen","year":"2024","journal-title":"Semin Nephrol"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151477_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11143939","article-title":"Hospital-acquired anemia in patients hospitalized in the intensive care unit: A retrospective cohort study","volume":"11","author":"Czempik","year":"2022","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151477_bib0007","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrneph.2011.88","article-title":"What are the anticoagulation options for intermittent hemodialysis?","volume":"7","author":"Davenport","year":"2011","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0008","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/sdi.12932","article-title":"Anticoagulation in hemodialysis: A narrative review","volume":"34","author":"Claudel","year":"2021","journal-title":"Semin Dial"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2012.03.017","article-title":"Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis","volume":"60","author":"Shen","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151477_bib0010","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"issue":"2 suppl","key":"10.1016\/j.semnephrol.2023.151477_bib0011","doi-asserted-by":"crossref","first-page":"e24S","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia","year":"2012","journal-title":"Chest."},{"key":"10.1016\/j.semnephrol.2023.151477_bib0012","article-title":"Unfractionated heparins, LMWH, direct thrombin inhibitors\u2014global perspectives of dosing regimens, guidelines and healthcare economics","author":"Santos","year":"2023","journal-title":"Semin Nephrol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0013","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12882-017-0596-4","article-title":"Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: A systematic review and meta-analysis","volume":"18","author":"Lazrak","year":"2017","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0014","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1038\/ki.1985.204","article-title":"Low molecular weight heparin in hemodialysis and hemofiltration patients","volume":"28","author":"Schrader","year":"1985","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151477_bib0015","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/ndt\/14.8.1943","article-title":"A single dose of dalteparin effectively prevents clotting during haemodialysis","volume":"14","author":"Sagedal","year":"1999","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-3848(86)90039-3","article-title":"Low molecular weight heparin half life is prolonged in haemodialysed patients","volume":"43","author":"Goudable","year":"1986","journal-title":"Thromb Res"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1592\/phco.21.2.169.34113","article-title":"The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease","volume":"21","author":"Brophy","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151477_bib0018","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/ndt\/gfg396","article-title":"Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis","volume":"18","author":"Guillet","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"24","key":"10.1016\/j.semnephrol.2023.151477_bib0019","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1161\/01.CIR.103.24.2994","article-title":"Guide to anticoagulant therapy: Heparin","volume":"103","author":"Hirsh","year":"2001","journal-title":"Circulation."},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151477_bib0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.7326\/0003-4819-119-9-199311010-00002","article-title":"The weight-based heparin dosing nomogram compared with a \u201cstandard care\u201d nomogram. A randomized controlled trial","volume":"119","author":"Raschke","year":"1993","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11051338","article-title":"Monitoring of unfractionated heparin therapy in the intensive care unit using a point-of-care aPTT: A comparative, longitudinal observational study with laboratory-based aPTT and anti-Xa activity measurement","volume":"11","author":"Lardinois","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0022","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2146\/ajhp090123","article-title":"Weight-based heparin protocol using antifactor Xa monitoring","volume":"67","author":"Smith","year":"2010","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0023","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","article-title":"Renal Association Clinical Practice Guideline on haemodialysis","volume":"20","author":"Ashby","year":"2019","journal-title":"BMC Nephrol"},{"issue":"suppl_7","key":"10.1016\/j.semnephrol.2023.151477_bib0024","first-page":"64","article-title":"V.2 Prevention of clotting in the HD patient with normal bleeding risk","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl_7","key":"10.1016\/j.semnephrol.2023.151477_bib0025","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/ndt\/17.suppl_7.66","article-title":"V.3 Prevention of clotting in the HD patient with elevated bleeding risk","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0026","article-title":"Risk for excessive anticoagulation during hemodialysis is associated with type of vascular access and bedside coagulation testing: Results of a cross-sectional study","volume":"9","author":"De Troyer","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/hdi.12788","article-title":"Does subjective assessment of dialyzer appearance reflect dialyzer performance in online hemodiafiltration?","volume":"24","author":"Fazendeiro Matos","year":"2020","journal-title":"Hemodial Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0028","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/sdi.12380","article-title":"Anticoagulation in chronic hemodialysis: Progress toward an optimal approach","volume":"28","author":"Kessler","year":"2015","journal-title":"Semin Dial"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0029","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1525-1594.1979.tb03807.x","article-title":"Low-dose heparin in routine hemodialysis monitored by activated partial thromboplastin time","volume":"3","author":"Shapiro","year":"1979","journal-title":"Artificial Organs"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0030","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11096-020-01004-5","article-title":"Unfractionated heparin dosing in obese patients","volume":"42","author":"George","year":"2020","journal-title":"Int J Clin Pharm"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151477_bib0031","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1056\/NEJM197208172870703","article-title":"A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time","volume":"287","author":"Basu","year":"1972","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0032","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1093\/ajcp\/36.3.212","article-title":"The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies","volume":"36","author":"Proctor","year":"1961","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0033","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1055\/s-0038-1650358","article-title":"The therapeutic range for heparin therapy: Relationship between six activated partial thromboplastin time reagents and two heparin assays","volume":"75","author":"Kitchen","year":"1996","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0034","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.thromres.2011.11.016","article-title":"Monitoring unfractionated heparin with APTT: A French collaborative study comparing sensitivity to heparin of 15 APTT reagents","volume":"129","author":"Gouin-Thibaut","year":"2012","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0035","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archinte.161.3.385","article-title":"Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin","volume":"161","author":"Bates","year":"2001","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151477_bib0036","first-page":"782","article-title":"College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: Laboratory monitoring of unfractionated heparin therapy","volume":"122","author":"Olson","year":"1998","journal-title":"Arch Pathol Lab Med"},{"issue":"3 suppl","key":"10.1016\/j.semnephrol.2023.151477_bib0037","doi-asserted-by":"crossref","first-page":"188S","DOI":"10.1378\/chest.126.3_suppl.188S","article-title":"Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy","volume":"126","author":"Hirsh","year":"2004","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0038","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1182\/blood.V49.2.171.171","article-title":"Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis","volume":"49","author":"Chiu","year":"1977","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semnephrol.2023.151477_bib0039","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1001\/archinte.1996.00440140107010","article-title":"The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin","volume":"156","author":"Anand","year":"1996","journal-title":"Arch Intern Med"},{"issue":"17","key":"10.1016\/j.semnephrol.2023.151477_bib0040","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1001\/archinte.159.17.2029","article-title":"Recurrent venous thrombosis and heparin therapy: An evaluation of the importance of early activated partial thromboplastin times","volume":"159","author":"Anand","year":"1999","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0041","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/hdi.12563","article-title":"Efficacy and safety of low-dose heparin in hemodialysis","volume":"22","author":"Murea","year":"2018","journal-title":"Hemodial Int"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151477_bib0042","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/bjh.15013","article-title":"Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin time","volume":"183","author":"Erdem-Eraslan","year":"2018","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0043","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1365-2141.2011.08990.x","article-title":"False prolongation of the activated partial thromboplastin time (aPTT) in inflammatory patients: Interference of C-reactive protein","volume":"157","author":"van Rossum","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0044","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the APTT for monitoring unfractionated heparin?","volume":"157","author":"Arachchillage","year":"2017","journal-title":"Thromb Res"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ijlh.12071","article-title":"Emergency assessment of hemostasis in the bleeding patient","volume":"35","author":"Chandler","year":"2013","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0046","first-page":"M687","article-title":"Sensitivity of the azure heparin assay and comparisons with activated clotting time and whole blood partial thromboplastin time","volume":"36","author":"Salley","year":"1990","journal-title":"ASAIO Trans"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0047","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1161\/01.CIR.91.5.1568","article-title":"Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis","volume":"91","author":"Carteaux","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0048","doi-asserted-by":"crossref","first-page":"e00146","DOI":"10.1016\/j.plabm.2019.e00146","article-title":"Performance of 6 routine coagulation assays on the new Roche Cobas t711 analyzer","volume":"17","author":"Oostendorp","year":"2019","journal-title":"Pract Lab Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151477_bib0049","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1525-1594.1990.tb02996.x","article-title":"Usefulness of thrombelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis","volume":"14","author":"Shinoda","year":"1990","journal-title":"Artif Organs"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH08-08-0528","article-title":"Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation","volume":"101","author":"Chia","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0051","doi-asserted-by":"crossref","DOI":"10.1177\/1076029620975494","article-title":"Activated clotting time (ACT) for monitoring of low-dose heparin: Performance characteristics in healthy adults and critically ill patients","volume":"26","author":"Wehner","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0052","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1051\/ject\/200537265","article-title":"The effect of temperature and aprotinin during cardiopulmonary bypass on three different methods of activated clotting time measurement","volume":"37","author":"Machin","year":"2005","journal-title":"J Extra Corpor Technol"},{"issue":"1 suppl","key":"10.1016\/j.semnephrol.2023.151477_bib0053","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151477_bib0054","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/j.1875-9114.2011.01049.x","article-title":"Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin","volume":"32","author":"Vandiver","year":"2012","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0055","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0056","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1055\/s-0038-1646407","article-title":"Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis","volume":"66","author":"Ryan","year":"1991","journal-title":"Thromb Haemost"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151477_bib0057","first-page":"643","article-title":"Objective assessment of heparin requirements for hemodialysis in humans","volume":"103","author":"Ireland","year":"1984","journal-title":"J Lab Clin Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0058","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/j.ajkd.2007.12.040","article-title":"Pharmacodynamics of unfractionated heparin during and after a hemodialysis session","volume":"51","author":"Brunet","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0059","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/j.1542-4758.2012.00733.x","article-title":"Heparin-grafted dialysis membrane allows minimal systemic anticoagulation in regular hemodialysis patients: A prospective proof-of-concept study","volume":"17","author":"Kessler","year":"2013","journal-title":"Hemodial Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0060","first-page":"217","article-title":"Monitoring of heparins in haemodialysis using an anti-factor-Xa-specific whole-blood clotting assay","volume":"10","author":"Harenberg","year":"1995","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0061","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price","year":"2013","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0062","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/ajcp\/aqab135","article-title":"From activated partial thromboplastin time to antifactor Xa and back again","volume":"157","author":"May","year":"2022","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0063","doi-asserted-by":"crossref","DOI":"10.1177\/1076029619876030","article-title":"Evaluation of antifactor-Xa heparin assay and activated partial thromboplastin time values in patients on therapeutic continuous infusion unfractionated heparin therapy","volume":"25","author":"McLaughlin","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7-8","key":"10.1016\/j.semnephrol.2023.151477_bib0064","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1345\/aph.1Q161","article-title":"Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion","volume":"45","author":"Guervil","year":"2011","journal-title":"Ann Pharmacother"},{"issue":"17 suppl 2","key":"10.1016\/j.semnephrol.2023.151477_bib0065","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.2146\/sp150016","article-title":"Comparison of unfractionated heparin protocols using antifactor Xa monitoring or activated partial thrombin time monitoring","volume":"72","author":"Frug\u00e9","year":"2015","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151477_bib0066","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ajcp\/aqy156","article-title":"Discordant partial thromboplastin time (PTT) vs anti-Xa heparin activity","volume":"151","author":"Khan","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.semnephrol.2023.151477_bib0067","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.thromres.2019.01.007","article-title":"Monitoring of heparins in antithrombin-deficient patients","volume":"175","author":"Croles","year":"2019","journal-title":"Thromb Res"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0068","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000091806","article-title":"Positive acute-phase inflammatory markers in different stages of chronic kidney disease","volume":"26","author":"Rom\u00e3o","year":"2006","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151477_bib0069","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1055\/s-0032-1319770","article-title":"Unfractionated heparin for the treatment of venous thromboembolism: Best practices and areas of uncertainty","volume":"38","author":"Cuker","year":"2012","journal-title":"Semin Thromb Hemost"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151477_bib0070","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1515\/cclm-2020-0130","article-title":"Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data","volume":"58","author":"Hollestelle","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151477_bib0071","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1111\/jth.14969","article-title":"Monitoring unfractionated heparin therapy: Lack of standardization of anti-Xa activity reagents","volume":"18","author":"Smahi","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0072","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.22222","article-title":"Test of the month: The chromogenic antifactor Xa assay","volume":"87","author":"Gehrie","year":"2012","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0073","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/ijlh.13188","article-title":"Hemolysis interference in 10 coagulation assays on an instrument with viscosity-based, chromogenic, and turbidimetric clot detection","volume":"42","author":"Hedeland","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151477_bib0074","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/aor.13467","article-title":"Interference in the anti-Xa heparin activity assay due to hemolysis and icterus during pediatric extracorporeal life support","volume":"43","author":"Khan","year":"2019","journal-title":"Artif Organs"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151477_bib0075","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.5858\/arpa.2013-0572-OA","article-title":"The influence of free hemoglobin and bilirubin on heparin monitoring by activated partial thromboplastin time and anti-Xa assay","volume":"138","author":"Kostousov","year":"2014","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151477_bib0076","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1177\/1076029617741363","article-title":"Performance of anti-factor Xa versus activated partial thromboplastin time for heparin monitoring using multiple nomograms","volume":"24","author":"Whitman-Purves","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100031","article-title":"Viscoelastic testing: An illustrated review of technology and clinical applications","volume":"7","author":"Hartmann","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151477_bib0078","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/ndt\/17.8.1457","article-title":"Sonoclot coagulation analysis: New bedside monitoring for determination of the appropriate heparin dose during haemodialysis","volume":"17","author":"Furuhashi","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151477_bib0079","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000190134","article-title":"Activated clotting time is not a sensitive parameter to monitor anticoagulation with low molecular weight heparin in hemodialysis","volume":"76","author":"Greiber","year":"1997","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0080","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000479390","article-title":"Practical value of anti-Xa activity in the evaluation of extracorporeal circuit anticoagulation during haemodialysis: Results of a cross-sectional single-centre study","volume":"137","author":"Coene","year":"2017","journal-title":"Nephron"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151477_bib0081","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/nep.13122","article-title":"Correlation between activated partial thromboplastin time and anti-Xa activity in patients who received low-molecular weight heparin as anticoagulation for haemodialysis","volume":"22","author":"Wong","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151477_bib0082","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1097\/01.ASN.0000145014.80714.35","article-title":"Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: A meta-analysis of randomized trials","volume":"15","author":"Lim","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151477_bib0083","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1525-139X.2000.00052.x","article-title":"Anticoagulation for intermittent hemodialysis","volume":"13","author":"Ouseph","year":"2000","journal-title":"Semin Dial"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0084","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1093\/ndt\/16.5.987","article-title":"Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets","volume":"16","author":"Sagedal","year":"2001","journal-title":"Nephrol Dial Transplant"},{"issue":"1-2","key":"10.1016\/j.semnephrol.2023.151477_bib0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000348830","article-title":"Dalteparin dosing in high-flux haemodialysis and haemodiafiltration","volume":"122","author":"Sridharan","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151477_bib0086","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1093\/ckj\/sfaa057","article-title":"Efficacy of enoxaparin in preventing coagulation during high-flux haemodialysis, expanded haemodialysis and haemodiafiltration","volume":"14","author":"Santos","year":"2021","journal-title":"Clin Kidney J"},{"issue":"suppl 7","key":"10.1016\/j.semnephrol.2023.151477_bib0087","first-page":"63","article-title":"Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system","volume":"17","year":"2002","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0088","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1053\/j.ajkd.2015.07.015","article-title":"KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update","volume":"66","author":"Daugirdas","year":"2015","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151477_bib0089","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s00108-017-0220-5","article-title":"[Anticoagulation in patients with chronic kidney disease: Recommendations from the working group \u201cHeart-Kidney\u201d of the German Cardiac Society and the German Society of Nephrology]","volume":"58","author":"Schlieper","year":"2017","journal-title":"Internist (Berl)"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001870?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523001870?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T14:50:40Z","timestamp":1748357440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523001870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0270929523001870"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151477","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Laboratory Monitoring of Heparin Anticoagulation in Hemodialysis: Rationale and Strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151477","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"151477"}}